FDA Tobacco Committee Meets: Comments Sought
Published Date: 11/24/2025
Notice
Summary
The FDA is hosting a public online meeting on January 22, 2026, where experts will discuss tobacco product rules and give advice. Anyone interested can share their thoughts by January 21, 2026, through a public comment system. This meeting affects tobacco companies, public health groups, and anyone curious about tobacco safety and regulations.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
TPSAC will review ZYN MRTP applications
On January 22, 2026, the Committee will discuss modified risk tobacco product applications submitted by Swedish Match USA, Inc. for a list of ZYN products (including Cool Mint, Peppermint, Spearmint, Wintergreen, Citrus, Coffee, Cinnamon, Smooth/Original, Chill/Classic, Menthol/Fresh in 3 mg and 6 mg variants). Discussion will focus on relative health risks, consumer understanding of proposed claims, and potential public health impact of a modified risk marketing order.
Public comment docket and deadlines
The FDA opened docket FDA-2025-N-0835 for public comments on the Tobacco Products Scientific Advisory Committee meeting. Electronic comments are accepted until 11:59 p.m. ET on January 21, 2026; comments received on or before January 7, 2026 will be provided to the Committee, while comments received after January 7, 2026 will be considered by FDA but not provided to the Committee.
Opportunity to give oral testimony
People who want to speak at the advisory committee must request to speak and submit a brief statement with names and contact information by 12:00 p.m. ET on December 31, 2025. Oral presentations are scheduled between about 1:00 p.m. and 2:00 p.m. ET on January 22, 2026, and FDA may run a lottery if there are more registrants than can be accommodated.
Meeting available online and captioned
The TPSAC meeting on January 22, 2026 (9:00 a.m. to 4:30 p.m. ET) will be held via an online video conferencing platform, will be captioned and recorded, and will be available at the provided YouTube live link on the day of the meeting. FDA intends to post background material no later than 2 business days before the meeting, and if not posted beforehand, will make materials available at the time of the meeting and post them after the meeting.
Disability accommodations request window
FDA will make efforts to accommodate persons with disabilities at the advisory committee meeting; if you require accommodations, you must contact the designated FDA official at least 7 days before the meeting.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-20767, Intercept Pharmaceuticals, Inc., et al.; Withdrawal of Approval of New Drug Application for OCALIVA (Obeticholic Acid) Tablets, 5 Milligrams and 10 Milligrams, and Three Abbreviated New Drug Applications for Obeticholic Acid Tablets, 5 Milligrams and 10 Milligrams
The FDA is officially pulling the approval for OCALIVA tablets (5 mg and 10 mg) and similar versions from three other companies, effective November 24, 2025. This affects patients, doctors, and pharmacies who use or sell these drugs, meaning they’ll need to find alternatives soon. The companies themselves asked for this change, so no surprise fees or penalties are involved.
Next: 2025-20769, Request for Information for 2027 Department of Defense (DoD) State Policy Priorities Impacting Service Members and Their Families
The Department of Defense is asking for ideas to help states make life easier for military members and their families in 2027. They want to fix problems like school changes for kids and retirement benefits for military spouses. This effort could lead to new state policies that save money and reduce stress for military families starting soon.